Recall wit­hout Pro­duct Risk – Dele­ga­ted Regu­la­ti­on (EU) 2024/3173

In accordance with Artic­le 26 of Regu­la­ti­on (EU) 2023/988 (GPSR), Mem­ber Sta­tes of the Euro­pean Uni­on must report cor­rec­ti­ve mea­su­res for dan­ge­rous pro­ducts that pose a serious risk within the mea­ning of the GPSR, as well as tho­se based on Artic­les 19 and 20 of Regu­la­ti­on (EU) 2019/1020 (Mar­ket Sur­veil­lan­ce Regu­la­ti­on). The noti­fi­ca­ti­on is made via the Safe­ty Gate Rapid Alert System.

In both cases, a serious risk is iden­ti­fied by a risk assess­ment. The cri­te­ria for this assess­ment were to be adopted by the Com­mis­si­on by means of a dele­ga­ted act. This was done on and with effect from 13 Decem­ber 2024 by Dele­ga­ted Regu­la­ti­on (EU) 2024/3173. The cri­te­ria for asses­sing the level of risk can be found in Annex II and lar­ge­ly fol­low tho­se of the pre­vious decis­i­on (RAPEX Gui­de­lines) (EU) 2019/417, with the excep­ti­on of Sec­tion 4: ‘Pre­sump­ti­on of a serious risk’.

In the cases spe­ci­fied the­re, a risk posed by a pro­duct is still requi­red, but it is pre­su­med to be a serious risk wit­hout the Mem­ber Sta­tes having to car­ry out an indi­vi­du­al risk assessment.

The Pre­sump­ti­on of a Serious Risk

The risk is actual­ly deter­mi­ned by the com­bi­na­ti­on of the seve­ri­ty of the harm and its pro­ba­bi­li­ty of occur­rence. Accor­ding to Sec­tion 3, Mem­ber Sta­tes are no lon­ger requi­red to car­ry out this assess­ment, but may do so. Taking into account the Eng­lish and French ver­si­ons, this assump­ti­on can be refu­ted by a risk assess­ment that is nevert­hel­ess car­ri­ed out. The pre­sump­ti­on is con­tro­ver­si­al becau­se Artic­le 19(1) of the Mar­ket Sur­veil­lan­ce Regu­la­ti­on gene­ral­ly pro­vi­des for the recall or with­dra­wal from the mar­ket of pro­ducts that pose a serious risk.

For exam­p­le, it is con­side­red a serious risk if the dis­tri­bu­tor of a pro­duct or the pro­vi­der of an online mar­ket­place assu­mes that the­re is a serious risk (Sec­tion 4.1(b)). The same appli­es if a pro­duct is vol­un­t­a­ri­ly remo­ved from a web­site (Sec­tion 4.1©). A serious risk is also assu­med if a pro­duct con­ta­ins a che­mi­cal sub­s­tance that should not be pre­sent under Uni­on law (Sec­tion 4.1(d)).

Unlawful­ness of the Dele­ga­ted Regulation

Alt­hough the Com­mis­si­on is tas­ked with estab­li­shing the cri­te­ria for asses­sing the level of risk, it may only sup­ple­ment the GPSR, not amend it. The very con­cept of risk (Art. 3 No. 4 GPSR) pre­sup­po­ses a rela­ti­onship bet­ween the pro­ba­bi­li­ty of a hazard occur­ring and the degree of seve­ri­ty of that harm. For the Com­mis­si­on, on the other hand, it is suf­fi­ci­ent that a pro­duct is to be asso­cia­ted with a pro­ba­ble level of dama­ge of 3 or 4 if con­su­mers can­not be reason­ab­ly expec­ted to take the neces­sa­ry pre­cau­ti­on mea­su­res – the pro­ba­bi­li­ty of occur­rence is irrele­vant. And the con­cept of a serious risk refers to ‘a risk which, based on a risk assess­ment (…)’ is con­side­red to requi­re rapid inter­ven­ti­on by the mar­ket sur­veil­lan­ce authorities.

The fact that the Com­mis­si­on is excee­ding its powers in this regard was the sub­ject of inten­se deba­te during this year’s Pro­duct Com­pli­ance Dia­lo­gue.

Sin­ce 5 March 2025, a lawsu­it has been pen­ding befo­re the ECJ with the aim of decla­ring Annex II, Sec­tion 4 of Dele­ga­ted Regu­la­ti­on (EU) 2024/3173 null and void (Case T‑154/25).

Con­clu­si­on

If the action is admis­si­ble, it has a good chan­ce of suc­cess. The ECJ has alre­a­dy ruled that legal reme­dies must be available against incom­ple­te RAPEX noti­fi­ca­ti­ons (Case C‑626/21). And an incor­rect pro­duct clas­si­fi­ca­ti­on can jus­ti­fy a cla­im for reme­di­al action (VG Müns­ter, judgment of 13 Novem­ber 2019 – 9 K 2514/16). Howe­ver, the Mem­ber Sta­tes are initi­al­ly bound by the Com­mis­si­on’s requirements.

The Dele­ga­ted Regu­la­ti­on does not app­ly to eco­no­mic ope­ra­tors. Manu­fac­tu­r­ers are alre­a­dy requi­red to report any assump­ti­on that a pro­duct is dan­ge­rous. Howe­ver, this is done via the Safe­ty Busi­ness Gate­way. In the accom­pany­ing manu­al, the Com­mis­si­on recom­mends that risk assess­ments be based on the Dele­ga­ted Regulation.

It remains to be seen how the aut­ho­ri­ties will imple­ment the gui­de­lines. They still have the right to car­ry out an indi­vi­du­al risk assess­ment that refu­tes the presumption.

back

Stay up-to-date

We use your email address exclusively for sending our newsletter. You have the right to revoke your consent at any time with effect for the future. For further information, please refer to our privacy policy.